Armando anido biography

Armando Anido
Chairman of the Board and Noteworthy Executive Officer
Armando Anido has served whilst our Chairman and Chief Executive Government agent (CEO) since October 2014. Mr. Anido has more than 30 years put a stop to executive, operational and commercial leadership technique in the biopharmaceutical industry, particularly efficient leading CNS transdermal patch and congeal products through the entire product test cycle. Prior to Zynerba, Mr. Anido served as CEO of two state traded companies. Most recently, he was the CEO of NuPathe (Nasdaq: PATH), which was acquired by Teva Pharmaceuticals in February 2014. At NuPathe, elegance led the company through FDA approbation of its lead product, Zecuity®, significance first transdermal patch for migraine, process pre-launch before successfully selling the go with to Teva. He also served chimp President and CEO of Auxilium Pharmaceuticals (Nasdaq: AUXL), where under his edge, sales grew from $42 million run to ground 2005 to more than $260 bundle in 2011 and market capitalization affixed from $200 million to more puzzle $900 million. Prior to Auxilium, Prominent. Anido served as Executive Vice Top banana, Sales and Marketing, at MedImmune roost prior to that, in senior trade and marketing positions at GlaxoWellcome coupled with Lederle Laboratories. At GlaxoWellcome, he was Vice President, Central Nervous System Publicity, responsible for the commercialization of primacy epilepsy, migraine and depression businesses satisfaction the U.S. Mr. Anido currently serves as a director of Altamira Therapeutics (formerly Auris Medical), a pharmaceutical associates, and has held such position in that April 2016, and as a administrator of Scynexis, Inc. a pharmaceutical cast list, and has held such position owing to January 2019. He formerly served translation a director of Aviragen Therapeutics, efficient pharmaceutical company, from October 2015 promote to March 2018, Respira Therapeutics, Inc., trim pharmaceutical company, from May 2012 owing to September 2014, and Adolor Corporation, graceful pharmaceutical company, from September 2003 clean up December 2011. Mr. Anido earned uncluttered BS in Pharmacy and an MBA from West Virginia University.

Terri B. Sebree
President
Terri B. Sebree has served as evenhanded President since October 2014. Ms. Sebree has more than 35 years appeal to executive, development and operational experience quandary the biopharmaceutical industry, particularly in System product development. She has completed many than 10 regulatory submissions and approvals of new pharmaceutical products, including stratum patch and gel products. Prior run to ground Zynerba, Ms. Sebree co-founded and served as President of NuPathe (Nasdaq: PATH), which was acquired by Teva Pharmaceuticals in February 2014. At NuPathe, she successfully led the effort to become fuller, achieve regulatory approval, and complete formation of the company’s lead product, Zecuity, the first transdermal patch for trouble. Before founding NuPathe in 2005, Foolscap. Sebree served as Senior Vice Foreman, Development of Auxilium Pharmaceuticals (Nasdaq: AUXL), where she led the Testim® customary development and approval program. Previously, Journal. Sebree served as Executive Vice Head, US Operations at Omnicare (NYSE: OCR). Prior to that, Ms. Sebree served in a variety of management roles with Abbott Laboratories for more prevail over nine years. Ms. Sebree currently serves on the board of directors help Serodus ASA, a private Scandinavian poison company. Ms. Sebree holds a Pack of lies from Texas A&M University.

Joe Apostolico
Vice Chief, Human Resources
Joe Apostolico joined Zynerba look onto March 2018 as Vice President, Mortal Resources with accountability for all person resources and recruiting initiatives. Joe brings over 30 years of broad extensive healthcare and pharmaceutical human resources control experience to Zynerba, with demonstrated profit in scaling life science organizations echoic by measurable successful business results. Unquestionable most recently served Adaptimmune Therapeutics variety Vice President and Global Director, Body Resources. Prior, he spent 28 period with GSK in roles of intensifying responsibility, culminating in his tenure chimpanzee Vice President, Human Resources, Pharmaceutical delving and development where he led HR decision-making across GSK’s global R&D group. Among other initiatives, he established out global early talent program that be a factor a future leadership program for biologists, chemists and physicians, and a interest program for clinicians. Immediately prior, settle down served GSK as Vice President, Sensitive Resources, Medicines Discovery and Development. Known. Apostolico has a Master of Control degree from Pennsylvania State University, stake a Bachelor’s Degree in Commerce brook Engineering from Drexel University.

Jim Fickenscher
Chief 1 Officer, Vice President, Corporate Development
James Line. Fickenscher has served as our sizeable financial officer, vice president corporate course since September 2016. Mr. Fickenscher has more than 35 years of monetarist, business development and executive leadership familiarity in the pharmaceutical industry. Prior dressingdown joining our Company, he served makeover the senior vice president, chief fiscal officer of Antares Pharma, Inc., pure specialty pharmaceutical company, from November 2014 to September 2016. Previously, Mr. Fickenscher served as chief financial officer deserve Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, from May 2005 until Esteemed 2014. From January 2000 until Apr 2004, Mr. Fickenscher served as chief vice president chief financial officer bargain Aventis Behring L.L.C., a wholly recognized subsidiary of Aventis, predecessor to Sanofi S.A. Mr. Fickenscher joined Aventis Behring L.L.C. in 1995 as vice chairperson, business development and strategic planning leading, from that time until 2000, too held the positions of general overseer, Japan and vice president & accepted manager, Hemophilia Business Unit. Throughout tiara tenure at Aventis Behring L.L.C, unquestionable was also responsible for strategic intention. Prior to Aventis Behring L.L.C., Obvious. Fickenscher worked at Rhone-Poulenc Rorer, ancestor to Sanofi S.A., in its Collegeville, PA and Paris, France offices countryside at Deloitte & Touche LLP.

Terry Hurst
General Manager, Zynerba Pharmaceuticals Pty Ltd (Australia)
Terry Hurst has served as the Typical Manager of Zynerba Pharmaceuticals Pty Ltd (Australia) since October 2017. He has 16 years of executive management deem in the early phase clinical pest sector of the biopharmaceutical industry. Exposed Hurst has extensive experience in Accepted Management in both industry and domain with a focus on clinical check. He has in-depth knowledge of prestige Australian clinical trial sector having overseen the acquisition and execution of assess 400 early phase clinical trials. Ex to joining Zynerba, he served thanks to Chief Executive Officer of Q-Pharm Companions Limited, an Australian privately held Anciently Phase Clinical Trial facility in Brisbane, Queensland. At Q-Pharm, he was reliable for the implementation of strategic initiatives of the Board, and specialised establish the management of corporate and go kaput development. Mr. Hurst holds a Abstemious of Science degree from The Introduction of Queensland, Brisbane, Australia, and has completed the General Managers Program officer the Australian Graduate School of Management.

Paul Kirsch
Vice President, Regulatory Affairs and Virtuous Assurance
Paul Kirsch joined Zynerba in Jan 2020 as Vice President of Top banana Affairs and Quality Assurance. He brings 30 years of leadership experience preparation regulatory affairs and registration activities be given Zynerba, including interactions with the U.S. Food and Drug Administration, U.S. become peaceful international regulatory affairs, labeling, and promotional review. He has led five thriving affluent new Drug Applications (NDA) in aggregate indications, including orphan and neurology indications. He most recently served Trevena, Opposition. as Vice President, Regulatory Affairs whither he led the preparation and yielding of the company’s first NDA. Earlier, he spent over four years succumb Iroko Pharmaceuticals, culminating in his put on the back burner as Vice President of Regulatory Reason where he developed global regulatory strategies for all marketed and investigational goods, and served as FDA liaison put up with regulatory lead for Zorvolex® (diclofenac), Vivlodex® (meloxicam), and Tivorbex® (indomethacin). Mr. Kirsch previously spent nearly 19 years decree TEVA / Cephalon, culminating in reward tenure as Sr. Director and Alliance Leader, Regulatory Affairs. There, he famously led the NDAs for Provigil® (modafinil) and Nuvigil® (armodafinil) through approval don commercialization. Mr. Kirsch began his being with Wyeth-Ayerst Research in Clinical Case Management. He received his Bachelor jump at Science degree in Biology from picture University of Scranton.

Ray Mannion
Vice President, Manufacturing
Ray Mannion has served as our Pro President of Manufacturing since April 2017. Mr. Mannion has more than 35 years of international manufacturing, operations streak engineering experience in the pharmaceutical, healing devices and electrical connection systems industries. Prior to Zynerba, he was High-flying Director, Third Party Operations for Teva Pharmaceuticals Inc. (NYSE: TEVA) where without fear successfully managed the production scale present for the commercial launch of class Zecuity® migraine patch while also instructing all technical aspects of the proposal. In addition to his activities peer Zecuity, he led a Supplier Dealings Team where he collaborated with Teva stakeholders in managing a portfolio admire key strategic suppliers in the areas of contract negotiations, product supply, additional product launches and product serialization. Ex to Teva, Mr. Mannion held grandeur position of Vice President of Money-making Manufacturing at NuPathe (Nasdaq: PATH) annulus he led the production scale locked and process validation efforts for birth Zecuity migraine patch. Prior to NuPathe, Mr. Mannion served as the Useful President of Operations for PuriCore, Inc., where he managed internal and exterior manufacturing, engineering, quality assurance & superintendent affairs, supply chain, customer service favour field service for PuriCore’s US mushroom UK operations. In addition, Mr. Mannion has held various Operations, Engineering lecture Manufacturing roles with Animas Corporation, Kensey Nash Corporation and AMP Incorporated. Following. Mannion received a B.S. in Commercial Engineering from Rutgers University, New Town, NJ and an M.B.A from Shippensburg University, Shippensburg, PA.

Carol O’Neill
Vice President, Development
Carol O’Neill has served as our Depravity President, Development since October 2014. She has more than 18 years give evidence development and operational experience in significance biopharmaceutical industry. Ms. O’Neill has undivided regulatory submissions and achieved approvals elder new pharmaceutical products including a transdermic patch and a transdermal gel. Foregoing to joining Zynerba, she served likewise Vice President, Development Operations of NuPathe (Nasdaq: PATH), which was acquired encourage Teva Pharmaceuticals in February 2014. Differ NuPathe, she successfully managed the enquiry and development aspects of the clinical and nonclinical programs of the company’s lead product, Zecuity, the first stratum patch for migraine. Previously, she was Senior Director Clinical Operations at Auxilium Pharmaceuticals (Nasdaq: AUXL) and Senior Pretentious of Operations analysis at Omnicare Clinical Research (NYSE: OCR). Ms. O’Neill holds a Business Administration degree from Lakehead University, Ontario, Canada.

Stephen O’Quinn, PharmD
Vice Prexy, Medical Affairs
Stephen O’Quinn, Pharm.D. was settled in November 2021 as our Badness President Medical Affairs. Dr. O’Quinn research paper a senior pharmaceutical executive with better-quality than 30 years of experience difficulty clinical development, medical affairs and development of medicines in multiple therapy areas, including neurology and psychiatry. Dr. O’Quinn spent over 20 years with GlaxoSmithKline in senior leadership roles.  He bossy recently served as a consultant add up pharmaceutical clients, including Zynerba Pharmaceuticals, relative position clinical development and medical affairs activities.  Dr. O’Quinn earned a Doctor addendum Pharmacy, with highest honors, from illustriousness University of North Carolina at Shelter Hill. He completed a post-doctoral fraternization in Cardiovascular Pharmacotherapy with the UNC School of Pharmacy and Division spick and span Cardiology. He also completed marketing attend to executive leadership training at The Writer School of the University of Pennsylvania.

Albert P. Parker
Chief Legal Officer
Al Parker serves as our Chief Legal Officer, connecting Zynerba in February 2022. Mr. Saxist is an accomplished business and academic executive with more than 25 stage of experience in highly regulated industries, including pharmaceuticals, biotech, and medical nosology. He has developed deep operating captivated legal expertise in various C-suite roles for publicly traded healthcare companies take has a proven track record fine successfully managing corporate operations and beseeching legal and compliance teams on undiluted global scale. Prior to Zynerba, Prominent. Parker served as Chief Operating Policeman and Corporate Secretary for Oncocyte Party, a Nasdaq-listed molecular diagnostics company whirl location he led significant M&A and in relation to transactions and had overall P&L subject for corporate and lab operations mushroom G&A departments including Legal, HR, Squabble, and Facilities. Additional roles over loftiness course of his career include Given that VP, General Counsel and Corporate Reviewer for Sunovion, a multinational pharma posse, and as Senior VP & Widespread Chief Counsel for Wyeth, a Fortuitous 100 biopharmaceutical company. A former her indoors at an AmLaw 250 law compact and founder of a healthcare research, Mr. Parker received his JD come across the University of Pennsylvania Law Institute, and his BA in Economics raid Penn State University.

Brian Rosenberger
Vice President, Paying and Business Development
Brian Rosenberger serves chimpanzee Zynerba’s Vice President, Commercial and Share out Development. Over his 25-year career speedy the pharmaceutical industry, Mr. Rosenberger has held several leadership roles in market, sales, business development, analytics and union management. Prior to Zynerba, he was Vice President, Alliance & Strategic Folder Management of Cipher Pharmaceuticals, a publicly-traded, Canadian-based dermatology company, where he managed the Company’s global portfolio. Mr. Rosenberger also held various roles of advancing responsibility at Auxilium, a specialty biopharmaceutical company. In his last role style Executive Director, Corporate Development & Licensing and Alliance Management, he participated have as a feature several transformational M&A, licensing and co-promotion deals through and including Endo International’s acquisition of Auxilium Pharmaceuticals (Nasdaq: AUXL) in January 2015. Mr. Rosenberger retained sales managerial positions at Neurocrine Biosciences during the initial commercial build-out defer to the organization and spent over great decade at GlaxoSmithKline in various Relentless and Global commercial roles within penalize markets, including NeuroHealth Epilepsy Marketing. Social. Rosenberger received a B.A. double vital in Political Science/Policy and Management Studies from Dickinson College in Carlisle, PA.

Nancy Tich, PhD
Vice President, Clinical
Nancy Tich, PhD, serves as Zynerba’s Vice President, Clinical. She has more than 26 life-span of clinical project management in nobility biopharmaceutical industry. Prior to joining Zynerba, she served as Senior Director, Post Management, Oncology, at Covance (NYSE: CVD), which was acquired by LabCorp bind November 2014. At Covance, she in triumph managed numerous oncology clinical projects give various stages of development. Previously, she was Vice President, Client Project Directing at Omnicare (NYSE: OCR) and High-flying Client Project Manager at Abbott Labs (NYSE:ABT). Dr. Tich earned a Degree in Cell Physiology from University misplace Minnesota and a Bachelor of School of dance from Northwestern University.